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Background/objectives: Bilirubin protects against oxidative stress-mediated diseases, especially atherosclerotic
diseases. On the other hand, subjects with carotid atherosclerosis have a high incidence of adverse cardiovascular
events. The aim of this studywas to evaluate the possible relationship between serum bilirubin levels and carotid
atherosclerosis in patients with coronary artery disease (CAD).
Methods:Weevaluated a total of 394patientswith chronic CAD, deﬁned as stable anginapectoris or a previousmyo-
cardial infarction. They were divided into four groups according to serum bilirubin level. Carotid intima–media
thickness and plaque score (PS) in the common carotid artery were measured using an ultrasound system. Severe
carotid atherosclerosis was deﬁned as PS N10.
Results:With increasing quartiles of serum bilirubin levels, the prevalence of severe carotid atherosclerosis signiﬁ-
cantly decreased (48.2%, 39.6%, 30.3%, and 27.0%, respectively, p for trend = 0.007). After adjusting for other risk
factors, low serum bilirubin levels were independently correlated with severe carotid atherosclerosis in CAD
patients (odds ratio 0.89, 95% conﬁdence interval, 0.81–0.99, p= 0.027).
Conclusion:Wedemonstrated that low serum bilirubin levels were associatedwith severe carotid atherosclerosis in
CAD patients. Our data suggest that serum bilirubin levels might be an independent, useful, and cost-effective tool
for evaluating atherosclerotic status in CAD patients.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
It is commonly accepted that bilirubin, themajor product of heme ca-
tabolism, has strong antioxidant properties that enable it to scavenge
peroxyl radicals and to inhibit oxidation of low-density lipoprotein-
derived lipids [1]. Several recent reports havedemonstrated that elevated
serumbilirubin levels provide important protective effects against oxida-
tive stress-mediated diseases, especially atherosclerotic diseases [2–4].
Increased carotid intima–media thickness (IMT) is awell-established
index of subclinical atherosclerosis and a risk factor for subsequent
cardiovascular disease (CVD) events [5–7]. It was recently reported
that greater carotid atherosclerosis is also associated with future
CVD events in high-risk patients [8,9]. Therefore, evaluation of carotidy, Nagoya University Graduate
466-8550, Japan. Tel.: +81 52
ability and freedom frombias of
nd Ltd. This is an open access article uatherosclerosis could be helpful in predicting future CVD events in
patients with chronic ischemic heart disease. However, few studies
have investigated the relationship between carotid atherosclerosis and
serum bilirubin levels in CAD patients. In the present study, we exam-
ined the association between serum bilirubin levels and carotid athero-
sclerosis in CAD patients.
2. Methods
2.1. Study subjects
This observational study included a total of 394 patients who were
treated for chronic CAD at Nagoya University Hospital between October
2011 and December 2013. Chronic CAD was deﬁned as stable angina
pectoris or a previous myocardial infarction. Patients were divided
into four groups according to quartiles of total bilirubin levels. The
exclusion criteria were as follows: acute cardiovascular events within
6 months before screening, previous carotid endarterectomy or carotid
artery stenting, chronic liver disease, acute heart failure, and hemodialy-
sis. Institutional ethics committee approval was obtained, and all patientsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Baseline characteristics.
Variables Quartiles of serum total bilirubin levels p, Trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Male gender 105 (77.8) 79 (82.3) 71 (79.8) 60 (81.1) 0.85
Age (years) 70.7 ± 9.2 69.9 ± 9.7 69.2 ± 9.0 68.0 ± 9.5 0.19
BMI (kg/m2) 23.5 ± 3.6 24.0 ± 3.9 23.1 ± 4.1 23.6 ± 3.8 0.90
Hypertension 108 (80.0) 74 (77.1) 72 (80.1) 53 (71.6) 0.47
Diabetes 58 (43.0) 37 (38.5) 44 (49.4) 27 (36.5) 0.33
Dyslipidemia 108 (80.0) 79 (82.3) 76 (85.4) 56 (75.7) 0.45
Current smoker 39 (29.5) 21 (23.6) 23 (28.0) 13 (17.6) 0.26
Multi vessel disease 105 (77.8) 69 (71.9) 57 (64.0) 54 (72.9) 0.17
Previous MI 27 (20.0) 23 (24.0) 20 (22.7) 13 (17.6) 0.74
Previous CI 21 (15.6) 12 (12.5) 11 (12.4) 10 (13.5) 0.89
AST (IU/l) 20.5 ± 5.6 21.1 ± 5.1 21.1 ± 6.2 21.2 ± 5.3 0.53
ALT (IU/l) 18.4 ± 7.6 19.1 ± 8.0 19.8 ± 8.9 18.9 ± 8.0 0.62
HDL (mg/dl) 46.9 ± 15.4 49.2 ± 13.5 46.6 ± 14.1 46.9 ± 11.2 0.39
LDL (mg/dl) 98.6 ± 30.7 104.7 ± 35.1 104.3 ± 29.3 103.6 ± 28.4 0.36
Triglycerides (mg/dl) 123 (87–176) 118 (83–163) 116 (90–168) 115 (73–149) 0.73
Fasting glucose (mg/dl) 109 (95–139) 108 (95–146) 109 (96–135) 101 (89–122) 0.12
Hemoglobin A1c (%) 6.2 ± 1.2 6.2 ± 1.1 6.2 ± 1.0 6.0 ± 1.1 0.52
Estimated GFR (ml/min/1.73 m2) 62.3 ± 22.0 66.5 ± 19.1 69.4 ± 17.9 69.4 ± 16.1 0.01
Proteinuria 33 (25.2) 12 (12.9) 15 (17.2) 9 (12.9) 0.06
C-reactive protein (mg/dl) 0.07 (0.03–0.14) 0.06 (0.03–0.12) 0.06 (0.04–0.11) 0.05 (0.03–0.10) 0.10
ACE-I or ARB 77 (57.0) 57 (59.3) 53 (59.6) 43 (59.0) 0.98
β-Blockers 40 (29.6) 30 (31.2) 30 (34.1) 21 (28.4) 0.86
Statins 84 (62.2) 66 (68.8) 60 (67.4) 49 (66.2) 0.74
Anti-diabetes drugs 57 (42.2) 34 (35.4) 44 (49.4) 24 (32.4) 0.11
Data are presented as mean ± SD, median (interquartile range), or n (%).
BMI, bodymass index; MI, myocardial infarction; CI, cerebral infarction; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; GFR, glomerular ﬁltration rate; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotension receptor blocker.
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body weight divided by height squared (kg/m2). After an overnight fast
of 12 h, blood sampleswere obtained fromall patients. Serum total biliru-
bin levels were measured by enzymatic methods using an autoanalyzer.
Hypertension was deﬁned as systolic blood pressure ≥140 mmHg,
diastolic blood pressure ≥90 mmHg, and/or current antihypertensive
medication use. Diabetes mellitus was deﬁned as the use of any anti-
hyperglycemic medication or a current diagnosis of diabetes or having a
fasting plasma glucose concentration N126 mg/dl or a glycosylated
hemoglobin concentration ≥6.5% (National Glycohemoglobin Stan-
dardization Program). Dyslipidemia was deﬁned as low-density
lipoprotein (LDL) cholesterol ≥140 mg/dl, high-density lipoprotein
cholesterol b40 mg/dl, triglycerides ≥150 mg/dl, or receiving lipid-
lowering therapy. Current smokers were deﬁned as those who
declared active smoking at all available examinations. The estimated
glomerular ﬁltration rate (eGFR) was calculated according to the
new Japanese equation: eGFR (ml/min/1.73 m2) = 194 × serum
creatinine − 1.094 × age − 0.287 × 0.739 (in females) [10]. Pro-
teinuria was deﬁned as a dipstick urinalysis score of 1+ or higher.Table 2
Data regarding carotid ultrasonography.
Variables Quartiles of serum total bilirubin levels
Quartile 1 Quartile 2
Max IMT (mm) 2.67 ± 0.95 2.33 ± 0.95
PS 9.9 ± 5.0 8.3 ± 5.1
PS severity
Normal (b1.1) 2 (1.5) 6 (6.3)
Mild (1.1–5) 18 (13.3) 18 (18.8)
Moderate (5.1–10) 50 (37.0) 34 (35.4)
Severe (N10) 65 (48.2) 38 (39.6)
Data are presented as mean ± SD or n (%).
IMT, intima–media thickness; PS, plaque score.2.2. Measurement of carotid atherosclerosis
Ultrasonography of the bilateral common carotid artery, carotid
bifurcation, and internal carotid artery was performed using a high-
resolution carotid ultrasound systemwith a 7.5-MHz linear array trans-
ducer (Prosound α10; Hitachi ALOKA Medical, Tokyo, Japan). IMT is
deﬁned as the distance from the leading edge of the ﬁrst echogenic
line to that of the second. The ﬁrst line represents the lumen–intima
interface, and the second line represents the collagen-containing upper
layer of the adventitia. Max IMT is deﬁned as maximal IMT of several
sites in the bilateral carotid arteries [11,12]. To assess the severity of
carotid atherosclerosis, plaque score (PS) was calculated by summing
all plaque thicknesses in eight segments, as proposed by Handa et al. [7,
12]. The severity of PSwas classiﬁed as normal, mild,moderate, or severe
if the total PS was b1.1, 1.1–5.0, 5.1–10.0, or N10.0, respectively. All mea-
surements were performed by a trained physician who was blinded to
the patients' clinical information. A total of 30 randomly selected persons
were measured for evaluation of inter- and intra-observer agreement.
The inter- and intra-observer variability of PS and max IMT were wellp, Trend
Quartile 3 Quartile 4
2.36 ± 1.05 2.27 ± 0.98 0.003
7.8 ± 4.9 7.9 ± 5.9 0.002
0.004
3 (3.4) 7 (9.5)
28 (31.5) 18 (24.3)
31 (34.8) 29 (39.2)
27 (30.3) 20 (27.0)
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[p b 0.001] and r= 0.97 [p= 0.001], respectively).2.3. Statistical methods
Statistical analyses were performed using SPSS, version 18.0 for
Windows (SPSS, Inc., Chicago, IL, USA). Data for normally distributed
continuous variables were expressed as mean ± standard deviation
(SD). Continuous variables that were not normally distributed were
expressed as median (interquartile range). Categorical variables were
expressed as numbers (percentages). Continuous variables were com-
pared using one-way ANOVA or the Kruskal–Wallis test. Categorical
variables were compared using the chi-square test or Fisher's exact
test. To obtain independent predictors of severe carotid atherosclerosis,
multivariate logistic regression analysis was performed for each param-
eter as a dependent variable. A two-sided p value of b0.05 was consid-
ered to indicate statistical signiﬁcance.3. Results
A total of 394 patients were analyzed in the present study. They
were divided into four groups according to quartiles of total bilirubin
levels as follows: quartile 1, total bilirubin of ≤0.5 mg/dl in 135 pa-
tients; quartile 2, total bilirubin of 0.6 mg/dl in 96 patients; quartile 3,
total bilirubin of 0.7–0.8 mg/dl in 89 patients; and quartile 4, total
bilirubin of≥0.9 mg/dl in 74 patients. Clinical variables for this popula-
tion, subdivided according to quartiles of total bilirubin levels, are
shown in Table 1. A signiﬁcant association was observed between
increased quartiles of total bilirubin and eGFR levels. Patients with low
serum bilirubin levels tended to be older, exhibited higher C-reactive
protein levels, and had a higher prevalence of proteinuria than those
with high bilirubin levels. However, other variables, such as body
mass index, lipid proﬁles, and the prevalences of hypertension and
diabetes mellitus, were comparable among the four groups.
Carotid ultrasonography ﬁndings in the enrolled patients are given
in Table 2. We observed that max IMT and PS signiﬁcantly decreased
across quartiles of total bilirubin levels (p for trend = 0.003 and p for
trend = 0.002, respectively). Moreover, we observed that the preva-
lence of severe carotid atherosclerosis signiﬁcantly decreased across
quartiles of serum bilirubin levels as follows: quartile 1, 48.2%; quartile
2, 39.6%; quartile 3, 30.3%; and quartile 4, 27.0%; p for trend = 0.007
(Fig. 1).Fig. 1.Association of total bilirubin levelswith the prevalence of severe carotid atheroscle-
rosis, deﬁned as a plaque score ofN10. The prevalence of severe carotid atherosclerosis sig-
niﬁcantly decreased across quartiles of serum bilirubin levels as follows: quartile 1, 48.2%;
quartile 2, 39.6%; quartile 3, 30.3%; and quartile 4, 27.0%; p for trend = 0.007.Even after multivariate adjusting for confounding factors, serum
bilirubin levels were independently associated with severe carotid ath-
erosclerosis in CAD patients [odds ratio 0.89, 95% conﬁdence interval
(CI), 0.81–0.99, p= 0.027, Table 3]. In a receiver operating curve analy-
sis, total bilirubin value b0.55 mg/dlwas identiﬁed as an effective cutoff
value for predicting severe carotid atherosclerosis (area under the
curve = 0.60, 95% CI, 0.55–0.66, p= 0.001).4. Discussion
The main ﬁnding of the present study was that reduced bilirubin
levels are associated with an increased risk of carotid atherosclerosis
among patientswith chronic CAD. These associationswere independent
after adjustment for traditional risk factors. Thus, bilirubin could serve
as a useful clinical biomarker for evaluating atherosclerotic status in
high-risk populations.
The relationship between bilirubin and the protective effects of
atherosclerosis is well known, but its underlying mechanisms are not
fully understood and some mechanisms have been proposed. It is well
established that bilirubin has antioxidant and anti-inﬂammatory activi-
ties in vitro [13,14]. This is supported by human studies reporting that
individuals with elevation in bilirubin levels due to Gilbert's syndrome
have higher antioxidant capacity and lower inﬂammatory markers
than control subjects [15–17]. Furthermore, several studies have fo-
cused on the association between bilirubin and endothelial function.
Erdogan et al. reported that lower serum bilirubin levels were related
to worse endothelial function in healthy patients [18]. Ishizaka et al.
reported that high serum bilirubin level is inversely associated with
carotid plaque among the population in general health screening tests
[19]. Mashitani et al. reported that serumbilirubin levelswere negative-
ly correlated with the progression of diabetic nephropathy [20]. Our
ﬁndings showed a signiﬁcant correlation between serum bilirubin
levels and carotid atherosclerosis. We speculate that elevated bilirubin
levels would inhibit oxidative stress and inﬂammation, resulting in
the prevention of atherosclerosis progression.
Previous studies have reported a negative correlation between
serum bilirubin levels and CVD in various populations [21–24]. More-
over, an association between serum bilirubin levels and adverse cardio-
vascular events has been reported. Huang et al. examined patients with
cardiac syndrome X and reported that those in the lowest bilirubin
tertile (≤0.6 mg/dl) had poorer clinical outcomes [25]. Chan et al.
reported that patients with type 2 diabetes who had lower bilirubin
levels had a higher incidence of lower limb amputation [26]. However,Table 3
Logistic regression analyses for severe carotid atherosclerosis.
Variables Simple regression Multiple regression
OR 95% CI p OR 95% CI p
Male 0.94 0.57–1.56 0.81
Age 1.07 1.04–1.09 b0.001 1.06 1.03–1.08 b0.001
Hypertension 1.83 1.08–3.08 0.02 1.71 0.99–2.96 0.055
HDL (mg/dl) 1.00 0.98–1.01 0.79
LDL (mg/dl) 1.00 0.99–1.00 0.32
Diabetes mellitus 1.13 0.75–1.70 0.55
Current smoking 1.35 0.84–2.16 0.21
Estimated GFR
(ml/mi/1.732)
0.98 0.97–0.99 0.001 0.99 0.98–1.00 0.14
Proteinuria 1.24 0.73–2.11 0.42
Log-transformed
C-reactive protein
0.78 0.45–1.34 0.36
Statin use 0.80 0.53–1.23 0.31
Total bilirubin
(per 0.1 mg increase)
0.86 0.79–0.95 0.002 0.89 0.81–0.98 0.02
Multivariate model includes all variables with p b 0.05 by univariate analysis.
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; GFR, glomerular ﬁltration rate.
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ischemic heart disease. Our ﬁndings might also provide an additional
explanation of the correlation between serum bilirubin levels and
worse clinical outcomes in patients in high-risk populations.
Several recent reports showed that the inverse association between
serum bilirubin levels and protective effects against atherogenesis was
stronger in men than in women. Moreover several reports showed the
relationship between low serum bilirubin levels and the risk of CVD in
men, but it was not clear inwomen [21,27,28]. The presence of estrogen
has been proposed as one of the mechanisms. Estrogen has anti-
atherosclerotic effects in itself, such as preventing the oxidative proper-
ties of LDL cholesterol, and producing the nitric oxide in the vascular
endothelial cell [29]. In this study, we also showed that lower serum
bilirubin levels had strong associationwith severe carotid atherosclero-
sis in men, but it was not shown in women [odds ratio 0.841, 95% con-
ﬁdence interval (CI) 0.75–0.94, p= 0.003 and odds ratio 1.144, 95% CI
0.90–1.45, p= 0.272, respectively] (data are not shown).
4.1. Study limitations
Several limitations of this study should be considered. First, it was an
observational analysis conducted in a single center and included a
relatively small sample. Second, we did not examine markers of oxida-
tive stress and endothelial function. Third, we had no information of
serum estrogen levels and hormone replacement therapy in female
patients. Finally, we had no data regarding changes in bilirubin levels
and the future progression of carotid atherosclerosis during the patients'
hospital stay.
4.2. Conclusions
In CAD patients, low serum bilirubin levels were independently
associated with severe carotid atherosclerosis. Our data suggest serum
bilirubin levels to be an independent, useful, and cost-effective tool for
evaluating atherosclerotic status in CAD patients.
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